Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neurizon Extends R&D Facility, Draws $12 Million Ahead Of ALS Trial Results

NUZ: $0.058 +1.75% · MC: $48M

Neurizon Therapeutics has extended its non-dilutive R&D financing facility to cover FY2027 and drawn approximately $3.7 million, bringing total advances to approximately $12 million before receiving the related tax rebates. Separately, the first participant in its HEALEY ALS trial’s Regimen I has entered the treatment extension after completing the randomised phase; topline results remain anticipated in late Q2 2027.

Source announcements: 2026-11-13 09:29 to 2026-11-13 09:39 Sydney time
Story updated 2026-11-13 09:45 Sydney time
SourcesR&D Facility Extension and Second Drawdown CompletedFirst Regimen I patient enters Active Treatment Extension
Comments